在我国失效的美国心血管疾病治疗药物的PCT 专利申请数据挖掘

目的：从没有在中国得到保护的美国专利申请或专利中寻找心血管疾病治疗药物研发的思路。方法：对申请日从2005 年1 月1 日至2014 年12 月31 日的美国心血管系统疾病治疗药物PCT 申请进入中国国家阶段后失效的专利申请及专利数据进行整序和分析，依据其在美国本土的法律状态确定其技术含金量。结果：未得到中国专利保护的美国心血管系统疾病治疗药物PCT 申请共174 件，其中170 件申请了美国优先权或进入了美国国家阶段。结论：170 件美国心血管系统疾病治疗药物PCT 申请在美国申请优先权，大多数因美国的优先权临时申请过期而放弃。14 件在美国本土的优先权申请失效，其所含信息量应该相当于公开发表的论文的信息量，23 件在美国本土优先权授权的专利技术具有一定的技术含金量，目前在中国已经进入公知公用领域，经过市场价值评估后可以无偿使用。

Data Mining of Invalid PCT Patent Applications in China of US Therapeutic Drugs for Cardiovascular Diseases

Objective: To look for R&D idea of drugs for treatment of cardiovascular diseases from the US patent applications or patents which are not protected in China. Methods: After PCT application of US drugs for treatment of cardiovascular diseases entered national phase in China, its patent application and patent data might become invalid. In this research, the above invalid patent application and patent data of PCT application, the filing date of which was from 2005-01-01 to 2014-12-31, were analyzed. Their technical values were determined according to their legal status in USA. Results: The number of PCT applications of US Therapeutic Drugs for Cardiovascular Diseases, which acquired no patent protection in China was 174. Among them, 170 PCT applications applied for the US priority or entering national phase in USA. Conclusion: 170 PCT applications were applied for the priority in USA, most of which were given up because of the overdue US priority. 14 priority applications in USA became invalid, the information amount of which was equal to that of published papers. 23 patent techniques acquiring priority authorization in USA had a certain value. They have already entered the known public field, and can be used free of charge after market value assessment.